Loading
A phase 1 trial of DFP-11207 run by Delta-Fly Pharma, Inc., completed.
Phase I Study of Oral DFP-11207 in Solid Tumors is a phase 1 interventional study registered as NCT02171221 by Delta-Fly Pharma, Inc., with 23 participants enrolled, started 2014-06. Conditions recorded: Solid Tumors and Cancer. Interventions recorded: Oral DFP-11207.
Shares Delta-Fly Pharma and the tag pipeline.
Shares Delta-Fly Pharma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Delta-Fly Pharma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Delta-Fly Pharma and the tag pipeline.
Shares Delta-Fly Pharma and the tag pipeline.
Shares Delta-Fly Pharma and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/